Compare Merck & Co., Inc. (MRK) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Advanced Drainage Systems Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Advanced Drainage Systems Inc trades at $125.79 (market cap $9.52B). The key difference: Merck & Co., Inc. is far larger — about 36.9× Advanced Drainage Systems Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Advanced Drainage Systems Inc for 43 Days on average.
| MRK | WMS | |
|---|---|---|
Market Cap | $351.28B | $9.52B |
Volume | 7,969,665 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $156.43 | $175.38 |
52-Week Low | $82.49 | $125.33 |
Typical Hold Time | 98 Days | 43 Days |
Enterprise Value | $398.04B | $11.12B |
Dividend Yield | 2.39% | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Advanced Drainage Systems (WMS) trades at $125.79, down 0.23% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with a P/E of 21.5 and robust profitability, including a 24.9% ROE. Recent quarterly earnings have consistently beaten estimates, and the company maintains a solid balance sheet with a debt-to-asset ratio of 34.34% as of 2025. A recent dividend declaration and sustainability report highlight ongoing corporate actions.
The outlook for WMS is positive given earnings beats and analyst consensus, but risks include a projected net cash flow decline in 2026 and competitive pressures. The stock presents a growth opportunity with a consensus price target of $188.70, though investors should weigh near-term cash flow trends against long-term fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
